Weak Lupus Positive Control
CRYOcheck Weak Lupus Positive Control is prepared from human source plasma and is recommended for use as a positive control in assays for lupus anticoagulant.
An association between circulating anticoagulants and systemic lupus erythematosus (SLE) was first described in 19521. In 1972 the term “lupus anticoagulant” (LA) was used to describe these non-specific, circulating inhibitors2. The designation LA is still used today although it is now evident the majority of these patients do not suffer from SLE3. The presence of LA has been increasingly associated with a variety of disorders such as unexplained thrombosis and recurrent fetal loss4,5.
LA are immunoglobulins, usually of the IgG, IgM or IgA classes,
which are directed against anionic phospholipids or phospholipidplasma protein complexes causing interference with in vitro phospholipid dependent coagulation tests. LA are clinically
distinct members of a broader group of antiphospholipid antibodies (APA) characterized by antigenic protein targets such as β2 glycoprotein 1 and prothrombin. APA include LA as well as anticardiolipin, antiphosphatidylserine, and antiphosphatidylethanolamine antibodies6,7,8.
The SSC Subcommittee for the Standardization of Lupus
Anticoagulants has specified four diagnostic criteria for LA9:
1) The prolongation of phospholipid-dependent clotting tests
such as the Kaolin Clotting Time (KCT)10, dilute Russell’s
Viper Venom Time (dRVVT)11, Tissue Thromboplastin
Inhibition Time (TTIT)3, or modified Activated Partial
Thromboplastin Time (APTT)12.
2) The inability to correct the defect by mixing with normal
(non-LA) plasma.
3) The relative correction of the defect through the addition of
washed, frozen-thawed platelets13 or hexagonal phase
phospholipids14.
4) Non-specificity to any individual clotting factor.
|
Register first to order your products
You are logged on as Guest. First register to order and to download product details
|
click to register
|
Login
Your order form